Changes to Cervical Screening

Information for Doctors

  • On December 1, 2017, the Cervical Screening Test (CST) replaced the PAP test.
  • The CST is the only Medicare-funded routine cervical screening test, and is available to women aged 25 to 74 years.
  • Specimens need to be collected by clinicians into ThinPrep® vials.
  • Request forms must specify the requested test, PLUS the reason for test, PLUS supporting clinical notes.

A risk-based approach

The CST uses an HPV DNA test to detect the presence of oncogenic HPV types known to be associated with a higher risk of developing significant cervical abnormalities. The HPV test is more sensitive than cytology, so it can be performed less frequently.

  • Asymptomatic women who test negative for oncogenic HPV are at low risk of developing cervical cancer and only need to be screened every 5 years.
  • Asymptomatic women who test positive for oncogenic HPV will have a liquid-based cytology (LBC) test performed on the same sample (reflex LBC) and will be assessed as either intermediate risk and advised to return for further testing in 12 months, or higher risk and referred for colposcopy.
  • Symptomatic women and those with a history of high-grade cervical pathology will have an HPV and LBC test (Co-test) performed, regardless of their HPV result.
  • Women with special circumstances may be offered more frequent screening or a single screening test prior to age 25.

Available resources

We have created a range of resources which are available to be downloaded from the links below.

Guide for Clinicians

Collection Guide

Flowchart - Transition to the National Cervical Screening Program & Test of Cure.

Flowchart - Pathway for routine cervical screening & Women with abnormal vaginal bleeding.

Information for Patients

Resource Order Form

Contact us

For further information on the new program, please contact us on 9371 4200.